E-therapeutics Regulatory News (ETX)

e-Therapeutics plc

("e-Therapeutics" or the "Company")

Result of General Meeting

On 15 February 2011, the Company announced the proposed placing of 67,740,904 new Ordinary Shares at 26 pence per share to raise gross proceeds of approximately £17.6 million. In order to allow qualifying investment to be made by certain venture capital trust funds, the fundraising will be effected in two stages referred to as the First Placing and the Second Placing (the "Placings").

The Placings are conditional, inter alia, upon (i) the resolutions being passed at the General Meeting; and (ii) admission of the relevant number of new Ordinary Shares to trading on AIM occurring on or before 8.00 a.m. on 4 March 2011 in respect of the First Placing and 7 March 20011 in respect of the Second Placing (or such later date as the parties may agree) ("Admission").

e-Therapeutics is pleased to announce that all resolutions proposed at the general meeting of the Company held this morning were duly passed by e-Therapeutics Shareholders. The Company is therefore pleased to announce that the Placings are unconditional in all respects subject to Admission.

Applications have been made to admit the total number of 67,740,904 new Ordinary Shares to be issued in the Placings to trading on AIM. Dealings in the new ordinary shares issued in the First Placing are expected to commence on 4 March 2011 and dealings in the new ordinary shares issued in the Second Placing are expected to commence on 7 March 2011.

Immediately following the First Placing, warrants over a further 3,299,111 new Ordinary Shares will be exercised (the "Warrant Exercise") and dealings in these new shares are also expected to take place on 4 March 2011 (application having been made for admission at the same time as new shares arising from the First Placing).

Following completion of the both the Placings and the Warrant Exercise, the number of ordinary shares in issue in the Company will become 137,193,547 on 7 March 2011.

The above figure (137,193,547ordinary shares) may be used from 7 March 2011 by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules. The current issued share capital remains 66,153,532 Ordinary Shares, increasing to 71,808,932 on 4 March.

For more information, please contact:

e-Therapeutics plc

Malcolm Young / John Cordiner

Tel: +44 (0) 191 233 1317

E-mail: malcolm@etherapeutics.co.uk

www.etherapeutics.co.uk

Panmure Gordon (UK) Limited

Andrew Burnett / Aubrey Powell

Tel: +44 (0) 20 7459 3600

www.panmure.com